1454890-28-8

Basic information

• Product Name: 4-((E)-1-(4-(2-(dimethylamino)ethoxy)phenyl)-2-phenylbut-1-enyl)phenyl 10-((Z)-2-((4-methoxy-1H,1'H-2,2'-bipyrrol-5-yl)methylene)-3,5-dimethyl-2H-pyrrol-4-yl)-10-oxodecanoate
• Synonyms: 4-((E)-1-(4-(2-(dimethylamino)ethoxy)phenyl)-2-phenylbut-1-enyl)phenyl 10-((Z)-2-((4-methoxy-1H,1'H-2,2'-bipyrrol-5-yl)methylene)-3,5-dimethyl-2H-pyrrol-4-yl)-10-oxodecanoate
• CAS NO: 1454890-28-8
• Molecular Weight: 821.072
• Mol File: 1454890-28-8.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 4-((E)-1-(4-(2-(dimethylamino)ethoxy)phenyl)-2-phenylbut-1-enyl)phenyl 10-((Z)-2-((4-methoxy-1H,1'H-2,2'-bipyrrol-5-yl)methylene)-3,5-dimethyl-2H-pyrrol-4-yl)-10-oxodecanoate(CAS DataBase Reference)
• NIST Chemistry Reference: 4-((E)-1-(4-(2-(dimethylamino)ethoxy)phenyl)-2-phenylbut-1-enyl)phenyl 10-((Z)-2-((4-methoxy-1H,1'H-2,2'-bipyrrol-5-yl)methylene)-3,5-dimethyl-2H-pyrrol-4-yl)-10-oxodecanoate(1454890-28-8)
• EPA Substance Registry System: 4-((E)-1-(4-(2-(dimethylamino)ethoxy)phenyl)-2-phenylbut-1-enyl)phenyl 10-((Z)-2-((4-methoxy-1H,1'H-2,2'-bipyrrol-5-yl)methylene)-3,5-dimethyl-2H-pyrrol-4-yl)-10-oxodecanoate(1454890-28-8)

Safety Data

• Hazardous Substances Data: 1454890-28-8(Hazardous Substances Data)

Upstream product

• 68047-06-3 Z-1-<4-(2-dimethylaminoethoxy)phenyl>-1-(4-hydroxyphenyl)-2-phenyl-1-butene 

Relevant articles and documents

Synthesis and biological evaluation of prodigiosene conjugates of porphyrin, estrone and 4-hydroxytamoxifen

To generate the first series of prodigiosene conjugates, the tripyrrolic skeleton was appended to estrone, tamoxifen and porphyrin frameworks by way of ester linkers and various hydrocarbon chain lengths. The ability of the conjugates to inhibit various types of cancer cells was evaluated in vitro. The porphyrin conjugates did not exhibit significant activity. The estrone conjugates exhibited modest activity, for the most part. However, significantly greater growth inhibition activity against certain breast, colon, lung, leukemia, melanoma and prostate cell lines was noted. This unusual effect for this first generation model class of compound warrants further investigation and comparison to cases where estrogens are linked to prodigiosenes via connection points that do not feature in estrogen receptor binding. The 4-hydroxytamoxifen conjugates exhibit nanomolar range activity against the MCF-7 breast cancer cell line, paving the way to expand the scope and connectivity of prodigiosene-tamoxifen conjugates.